Survey on Representations, Opinions and Perceptions regarding Psychoactive Drugs

The EROPP survey measures the French population's opinions and perceptions pertaining to psychotropic drugs and the related public actions. The 2013 survey was the fourth. The first three were conducted in 1999, 2002 and 2008. This telephone survey was based on a randomly surveyed, representative sample of the French population aged 15 to 75 years. The sample comprised households with a landline telephone (2,200) and people who used mobile phones only (300 individuals). The data were collected between 27 October and 25 December 2012.

The individuals were questioned about their use, their perception of the level of danger to health, their perception of users and public legal and illegal drug policies.


Ten years of change in French people's perceptions and opinions regarding drugs (1999-2008)
Tendances N° 71, August 2010

Drugs and public policies : changes in perceptions and opinions, 1999-2002
Tendances N° 28, January 2003

How do the French perceive heroin users?
Tendances N° 8, June 2000

Drugs and Drug Addiction, perceptions and opinions in 1999: First Results
Tendances N° 4, December 1999







Drugs in Europe

2021 EMCDDA European Drug Report

How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.